Box Office Recovery Supporting Theatrical Exhibitors -- Market Talk
Dow Jones2026/10/05 17:091309 ET - Fitch Ratings said North American theatrical exhibitors are being supported by improving box office trends and higher spending per patron. However, the sector's structural concerns remain key credit constraints, Fitch added. Structural headwinds including competition from streaming and dependence on film studios for content-supply. But fuller film slates and operating discipline are driving EBITDA growth and deleveraging, Fitch said. Premium large-format screens, attractive locations and strong concession economics put operators in a position to garner more revenue per visit, while smaller, less-well-capitalized operators, or those with inflexible cost structure, are more exposed to gaps in the slate, according to Fitch. (stephen.nakrosis@wsj.com) (END) Dow Jones Newswires October 05, 2026 13:09 ET (17:09 GMT)
1309 ET - Fitch Ratings said North American theatrical exhibitors are being supported by improving box office trends and higher spending per patron. However, the sector's structural concerns remain key credit constraints, Fitch added. Structural headwinds including competition from streaming and dependence on film studios for content-supply. But fuller film slates and operating discipline are driving EBITDA growth and deleveraging, Fitch said. Premium large-format screens, attractive locations and strong concession economics put operators in a position to garner more revenue per visit, while smaller, less-well-capitalized operators, or those with inflexible cost structure, are more exposed to gaps in the slate, according to Fitch. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
October 05, 2026 13:09 ET (17:09 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.
The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.
AiCoin丨10.16 Snapshot: PPI Exceeds Expectations, Russia Bans P2P, US Stock ETF Net Outflow
Yen barely gains on a BoJ push for hikes and a Tokyo stock rout
IEA agrees to release of outstanding 100 million barrels of oil
Crypto prices
More
